Expression and significance of HMGB1, TLR4 and NF-κB p65 in human epidermal tumors

BMC Cancer

Hui Weng²  Yunhua Deng¹  Yuyan Xie³  Hongbo Liu²  Feili Gong² 

[1] Department of Dermatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

[2] Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China

[3] Department of Pathology, The 5th Affiliated Hospital of Sun Yat-Sen University, Zhuhai 519000, China

关键词: Squamous cell carcinoma;    Precancerous lesions;    Seborrheic keratosis;    NF-κB;    TLR4;    HMGB1;   

Others  :  1079679
DOI  :  10.1186/1471-2407-13-311

 received in 2012-10-30, accepted in 2013-06-20,  发布年份 2013

【 摘 要 】

Background

High mobility group protein box 1 (HMGB1) is a DNA binding protein located in nucleus. It is released into extracellular fluid where it acts as a novel proinflammatory cytokine which interacts with Toll like receptor 4 (TLR4) to activate nuclear factor-κB (NF-κB). This sequence of events is involved in tumor growth and progression. However, the effects of HMGB1, TLR4 and NF-κB on epidermal tumors remain unclear.

Methods

Human epidermal tumor specimens were obtained from 96 patients. Immunohistochemistry was used to detect expression of HMGB1, TLR4 and NF-κB p65 in human epidermal tumor and normal skin specimens. Western blot analysis was used to detect the expression of NF-κB p65 in epithelial cell nuclei in human epidermal tumor and normal tissues.

Results

Immunohistochemistry and western blot analysis indicated a progressive but statistically significant increase in p65 expression in epithelial nuclei in benign seborrheic keratosis (SK), precancerous lesions (PCL), low malignancy basal cell carcinoma (BCC) and high malignancy squamous cell carcinoma (SCC) (P <0.01). The level of extracellular HMGB1 in SK was significantly higher than in normal skin (NS) (P <0.01), and was higher than in SCC but without statistical significance. The level of TLR4 on epithelial membranes of SCC cells was significantly higher than in SK, PCL, BCC and NS (P <0.01). There was a significant positive correlation between p65 expression in the epithelial nuclei and TLR4 expression on the epithelial cell membranes (r = 0.3212, P <0.01).

Conclusions

These findings indicate that inflammation is intensified in parallel with increasing malignancy. They also indicate that the TLR4 signaling pathway, rather than HMGB1, may be the principal mediator of inflammation in high-grade malignant epidermal tumors. Combined detection of p65 in the epithelial nuclei and TLR4 on the epithelial membranes may assist the accurate diagnosis of malignant epidermal tumors.

【 授权许可】

   
2013 Weng et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Barta P, Van Pelt C, Men T, Dickey BF, Lotan R, Moghaddam SJ: Enhancement of lung tumorigenesis in a Gprc5a knockout mouse by chronic extrinsic airway inflammation. Mol Cancer 2012, 11:4. BioMed Central Full Text
• [2]Kyewski B, Romero P: Chronic inflammation is regarded as a strong promoter of tumorigenesis. Int J Cancer 2010, 127(4):747.
• [3]Carothers AM, Davids JS, Damas BC, Bertagnolli MM: Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis. Cancer Res 2010, 70(11):4433-4442.
• [4]Jube S, Rivera Z, Bianchi ME, Powers A, Wang E, Pagano IS, Pass HI, Gaudino G, Carbone M, Yang H: Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 2012, 72(13):3290-3301.
• [5]Bianchi ME: DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81(1):1-5.
• [6]Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ: HMGB1 And RAGE in inflammation and cancer. Annu Rev Immunol 2010, 28:367-388.
• [7]Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, Dumitriu IE, Muller S, Iannacone M, Traversari C, et al.: HMGB1 Is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004, 5(8):825-830.
• [8]Dai S, Sodhi C, Cetin S, Richardson W, Branca M, Neal MD, Prindle T, Ma C, Shapiro RA, Li B, et al.: Extracellular high mobility group box-1 (HMGB1) inhibits enterocyte migration via activation of toll-like receptor-4 and increased cell-matrix adhesiveness. J Biol Chem 2010, 285(7):4995-5002.
• [9]Akaike H, Kono K, Sugai H, Takahashi A, Mimura K, Kawaguchi Y, Fujii H: Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer Res 2007, 27(1A):449-457.
• [10]Ellerman JE, Brown CK, De Vera M, Zeh HJ, Billiar T, Rubartelli A, Lotze MT: Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007, 13(10):2836-2848.
• [11]Tadie JM, Bae HB, Deshane JS, Bell CP, Lazarowski ER, Chaplin DD, Thannickal VJ, Abraham E, Zmijewski JW: TLR4 Engagement inhibits AMPK activation through a HMGB1 dependent mechanism. Mol Med 2012, 9(18):659-668.
• [12]Naugler WE, Karin M: NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 2008, 18(1):19-26.
• [13]Tang D, Kang R, Zeh HJ 3rd, Lotze MT: High-mobility group box 1 and cancer. Biochim Biophys Acta 2010, 1799(1–2):131-140.
• [14]Liu PL, Tsai JR, Hwang JJ, Chou SH, Cheng YJ, Lin FY, Chen YL, Hung CY, Chen WC, Chen YH, et al.: High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness. Am J Respir Cell Mol Biol 2010, 43(5):530-538.
• [15]Pacifico F, Leonardi A: NF-kappaB in solid tumors. Biochem Pharmacol 2006, 72(9):1142-1152.
• [16]Peek RM Jr, Fiske C, Wilson KT: Role of innate immunity in helicobacter pylori-induced gastric malignancy. Physiol Rev 2010, 90(3):831-858.
• [17]Ito Y, Bhawal UK, Sasahira T, Toyama T, Sato T, Matsuda D, Nishikiori H, Kobayashi M, Sugiyama M, Hamada N, et al.: Involvement of HMGB1 and RAGE in IL-1beta-induced gingival inflammation. Arch Oral Biol 2012, 57(1):73-80.
• [18]Agresti A, Lupo R, Bianchi ME, Muller S: HMGB1 Interacts differentially with members of the Rel family of transcription factors. Biochem Biophys Res Commun 2003, 302(2):421-426.
• [19]Kim SW, Lim CM, Kim JB, Shin JH, Lee S, Lee M, Lee JK: Extracellular HMGB1 released by NMDA treatment confers neuronal apoptosis via RAGE-p38 MAPK/ERK signaling pathway. Neurotox Res 2011, 20(2):159-169.
• [20]Nogueira-Machado JA, Volpe CM, Veloso CA, Chaves MM: HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation. Expert Opin Ther Targets 2011, 15(8):1023-1035.
• [21]Andersson U, Rauvala H: Introduction: HMGB1 in inflammation and innate immunity. J Intern Med 2011, 270(4):296-300.
• [22]Vitali R, Stronati L, Negroni A, Di Nardo G, Pierdomenico M, Del Giudice E, Rossi P, Cucchiara S: Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. Am J Gastroenterol 2011, 106(11):2029-2040.
• [23]Hashimoto C, Hudson KL, Anderson KV: The toll gene of drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 1988, 52(2):269-279.
• [24]Wu B, Huan T, Gong J, Zhou P, Bai Z: Domain combination of the vertebrate-like TLR gene family: implications for their origin and evolution. J Genet 2011, 90(3):401-408.
• [25]Cook DN, Pisetsky DS, Schwartz DA: Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004, 5(10):975-979.
• [26]Pandey SC: TLR4-MyD88 Signalling: a molecular target for alcohol actions. Br J Pharmacol 2012, 165(5):1316-1318.
• [27]Bauerfeld CP, Rastogi R, Pirockinaite G, Lee I, Huttemann M, Monks B, Birnbaum MJ, Franchi L, Nunez G, Samavati L: TLR4-Mediated AKT activation is MyD88/TRIF dependent and critical for induction of oxidative phosphorylation and mitochondrial transcription factor a in murine macrophages. J Immunol 2012, 188(6):2847-2857.
• [28]Hirano H, Yoshioka T, Yunoue S, Fujio S, Yonezawa H, Niiro T, Habu M, Oyoshi T, Sugata S, Kamezawa T, et al.: TLR4, IL-6, IL-18, MyD88 and HMGB1 are highly expressed in intracranial inflammatory lesions and the IgG4/IgG ratio correlates with TLR4 and IL-6. Neuropathology 2012, 32(6):628-637.
• [29]Ghosh S, Hayden MS: New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008, 8(11):837-848.
• [30]Karin M, Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005, 5(10):749-759.
• [31]Oeckinghaus A, Hayden MS, Ghosh S: Crosstalk in NF-kappaB signaling pathways. Nat Immunol 2011, 12(8):695-708.
• [32]Siggers T, Chang AB, Teixeira A, Wong D, Williams KJ, Ahmed B, Ragoussis J, Udalova IA, Smale ST, Bulyk ML: Principles of dimer-specific gene regulation revealed by a comprehensive characterization of NF-kappaB family DNA binding. Nat Immunol 2012, 13(1):95-102.
• [33]Espinosa L, Bigas A, Mulero MC: Alternative nuclear functions for NF-kappaB family members. Am J Cancer Res 2011, 1(4):446-459.
• [34]Yadav VR, Prasad S, Gupta SC, Sung B, Phatak SS, Zhang S, Aggarwal BB: 3-Formylchromone interacts with cysteine 38 in p65 protein and with cysteine 179 in IkappaBalpha kinase, leading to down-regulation of nuclear factor-kappaB (NF-kappaB)-regulated gene products and sensitization of tumor cells. J Biol Chem 2012, 287(1):245-256.
• [35]Baeuerle PA, Baltimore D: NF-kappa B: ten years after. Cell 1996, 87(1):13-20.
• [36]Sen R, Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986, 46(5):705-716.
• [37]Ohtsuka K, Hata M: Molecular chaperone function of mammalian Hsp70 and Hsp40–a review. Int J Hyperthermia 2000, 16(3):231-245.
• [38]Tsan MF, Gao B: Heat shock proteins and immune system. J Leukoc Biol 2009, 85(6):905-910.
• [39]Wallin RP, Lundqvist A, More SH, Von Bonin A, Kiessling R, Ljunggren HG: Heat-shock proteins as activators of the innate immune system. Trends Immunol 2002, 23(3):130-135.
• [40]Krause M, Rodrigues-Krause Jda C: Extracellular heat shock proteins (eHSP70) in exercise: possible targets outside the immune system and their role for neurodegenerative disorders treatment. Med Hypotheses 2011, 76(2):286-290.